HIV-associated renal and genitourinary comorbidities in Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue SUPPL.1, 2014, Pages

  Kalyesubula, Robert ^a,b   Wearne, Nicola ^c   Semitala, Fred C ^a,b,d   Bowa, Kasonde ^e  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b Mulago National Referral and Teaching Hospital   (Uganda)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d MAKERERE UNIVERSITY   (Uganda)

^e Lulea University of Technology   (Zambia)

Author keywords

Africa; antiretroviral therapy; HIV AIDS; kidney disease; noncommunicable diseases; urogenital disorders disease

Indexed keywords

AFRICA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE REGISTRY; DRUG EFFECT; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY INJURY; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; UROGENITAL TRACT DISEASE;

AFRICA; COMORBIDITY; FEMALE UROGENITAL DISEASES; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MALE UROGENITAL DISEASES; PREVALENCE;

EID: 84906057222     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000259     Document Type: Article

References (129)

1. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
2. Bor J, Herbst AJ, Newell ML, et al. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339:961-965.
3. Campbell LJ, Ibrahim F, Fisher M, et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10:329-336.
4. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.
5. Adih WK, Selik RM, Hu X. Trends in diseases reported on US death certificates that mentioned HIV infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic). 2011;10:5-11.
6. Etyang AO, Scott JA. Medical causes of admissions to hospital among adults in Africa: a systematic review. Glob Health Action. 2013;6:1-14.
7. Mayosi BM, Flisher AJ, Lalloo UG, et al. The burden of non-communicable diseases in South Africa. Lancet. 2009;374:934-947.
8. Kapiga S. Commentary: non-communicable diseases in sub-Saharan Africa: a new global health priority and opportunity. Int J Epidemiol. 2011;40:902-903.
9. Mayosi BM, Lawn JE, van Niekerk A, et al. Health in South Africa: changes and challenges since 2009. Lancet. 2012;380:2029-2043.
10. Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382: 158-169.
11. Assembly UNG. United nations general assembly. Political declaration of the high-level meeting of the general assembly on the prevention and control of non-communicable diseases. Paper presented at: 66th session: United Nations General Assembly, September 19-20, 2011, New York, NY.
12. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
13. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825-830.
14. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8: R204-R212.
15. Amdur RL, Chawla LS, Amodeo S, et al. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int. 2009;76:1089-1097.
16. Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302: 1179-1185.
17. Lo LJ, Go AS, Chertow GM, et al. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009;76:893-899.
18. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223-228.
19. Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int. 2010;78:478-485.
20. Arendse CG, Wearne N, Okpechi IG, et al. The acute, the chronic and the news of HIV-related renal disease in Africa. Kidney Int. 2010;78: 239-245.
21. Arendse C, Okpechi I, Swanepoel C. Acute dialysis in HIV-positive patients in Cape Town, South Africa. Nephrology (Carlton). 2011;16: 39-44.
22. Wyatt CM, Arons RR, Klotman PE, et al. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS. 2006;20:561-565.
23. Naicker S, Aboud O, Gharbi MB. Epidemiology of acute kidney injury in Africa. Semin Nephrol. 2008;28:348-353.
24. Cailhol J, Nkurunziza B, Izzedine H, et al. Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study. BMC Nephrol. 2011;12:40.
25. Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. Nat Rev Nephrol. 2009;5:591-598.
26. Mulenga LB, Kruse G, Lakhi S, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22:1821-1827.
27. Swanepoel CR, Wearne N, Okpechi IG. Nephrology in Africa-not yet uhuru. Nat Rev Nephrol. 2013;9:610-622.
28. Santos WJ, Zanetta DM, Pires AC, et al. Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit-a homogeneous population? Crit Care. 2006;10:R68.
29. Vachiat AI, Musenge E, Wadee S, et al. Renal failure in HIV-positive patients-a South African experience. Clin Kidney J. 2013;6:584-589.
30. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med. 2007;33:409-413.
31. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
32. Banda J, Mweemba A, Siziya S, et al. Prevalence and factors associated with renal dysfunction in HIV positive and negative adults at the University Teaching Hospital, in Lusaka. Med J Zambia. 2010; 37:136-142.
33. Kalyesubula R, Perazella M. HIV-related drug nephrotoxicity in sub-saharan africa. 2010;6. Available at: http://archive.ispub.com/journal/the- internet-journal-of-nephrology/archives.html#sthash.WyWbA85J. dpbs. Accessed July 20, 2013.
34. Hsu RK, McCulloch CE, Dudley RA, et al. Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol. 2013;24:37-42.
35. Abraham KA, Thompson EB, Bodger K, et al. Inequalities in outcomes of acute kidney injury in England. QJM. 2012;105:729-740.
36. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.
37. Longo AL, Lepira FB, Sumaili EK, et al. Prevalence of low estimated glomerular filtration rate, proteinuria, and associated risk factors among HIV-infected black patients using Cockroft-Gault and modification of diet in renal disease study equations. J Acquir Immune Defic Syndr. 2012;59:59-64.
38. 2. Am J Kidney Dis. 2010;56:486-495.
39. Wools-Kaloustian K, Gupta SK, Muloma E, et al. Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant. 2007;22:2208-2212.
40. D'Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989;35:1358-1370.
41. Han TM, Naicker S, Ramdial PK, et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006;69:2243-2250.
42. Wearne N, Swanepoel CR, Boulle A, et al. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant. 2012;27:4109-4118.
43. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int. 2006;69:1885-1891.
44. Carbone L, D'Agati V, Cheng JT, et al. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med. 1989;87: 389-395.
45. Levin ML, Palella F, Shah S, et al. HIV-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis. 2001;37:E39.
46. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40: 1175-1184.
47. Bates WD, Muller N, van de Wal BW, et al. HIV-associated nephropathy-an initial presentation in an HIV-positive patient. S Afr Med J. 1994;84: 223-224.
48. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128:345-350.
49. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22:2129-2137.
50. Pollak MR, Genovese G, Friedman DJ. APOL1 and kidney disease. Curr Opin Nephrol Hypertens. 2012;21:179-182.
51. Oleksyk TK, Nelson GW, An P, et al. Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa. PLoS One. 2010;5:e11474.
52. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183-2196.
53. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841-845.
54. Bostrom MA, Kao WH, Li M, et al. Genetic association and gene-gene interaction analyses in African American dialysis patients with nondia-betic nephropathy. Am J Kidney Dis. 2012;59:210-221.
55. Kopp JB. JC viruria and kidney disease in APOL1 risk genotype individuals: is this a clue to a gene x environment interaction? Kidney Int. 2013;84:1069-1072.
56. Ulasi II, Tzur S, Wasser WG, et al. High population Frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-Eastern Nigeria. Nephron Clin Pract. 2013;123:123-128.
57. Behar DM, Kedem E, Rosset S, et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol. 2011;34:452-459.
58. Jerico C, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens. 2005;18: 1396-1401.
59. De Socio GV, Bonfanti P, Martinelli C, et al. Negative influence of HIV infection on day-night blood pressure variability. J Acquir Immune Defic Syndr. 2010;55:356-360.
60. Mateen FJ, Kanters S, Kalyesubula R, et al. Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda. J Hypertens. 2013;31:1372-1378.
61. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60-69.
62. Oramasionwu CU, Morse GD, Lawson KA, et al. Hospitalizations for cardiovascular disease in African Americans and whites with HIV/AIDS. Popul Health Manag. 2013;16:201-207.
63. Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739-751.
64. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013;83:114-120.
65. Okunola O, Akinsola A, Ayodele O. Kidney diseases in Africa: aetiological considerations, peculiarities and burden. Afr J Med Med Sci. 2012;41:119-133.
66. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol. 2010;74(suppl 1):S51-S56.
67. Medapalli RK, Parikh CR, Gordon K, et al. Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr. 2012;60:393-399.
68. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380: 2095-2128.
69. Sliwa K, Davison BA, Mayosi BM, et al. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. Eur Heart J. 2013;34: 3151-3159.
70. Bygrave H, Kranzer K, Hilderbrand K, et al. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One. 2011;6:e17609.
71. De Beaudrap P, Diallo MB, Landman R, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses. 2010;26:1221-1227.
72. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603-1609.
73. Stohr W, Reid A, Walker AS, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16:1011-1020.
74. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochon-drial abnormalities. Kidney Int. 2010;78:1171-1177.
75. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal tox-icity targets mitochondria of renal proximal tubules. Lab Invest. 2009; 89:513-519.
76. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
77. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis. 2010;17:72-82.
78. Castelnuovo B, John L, Lutwama F, et al. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009;8:52-59.
79. Marseille E, Kahn JG, Pitter C, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy. 2009;7:229-243.
80. Fox MP, Ive P, Long L, et al. High rates of survival, immune recon-stitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53:500-506.
81. HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring. AIDS Patient Care STDS. 2009;23: 680-681.
82. Wyatt CM, Schwartz GJ, Owino Ong'or W, et al. Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. PLoS One. 2013; 8:e69601.
83. Stohr W, Walker AS, Munderi P, et al. Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and modification of diet in renal disease formulae. Antivir Ther. 2008; 13:761-770.
84. Samal L, Linder JA. The primary care perspective on routine urine dipstick screening to identify patients with albuminuria. Clin J Am Soc Nephrol. 2013;8:131-135.
85. Ulu UO, Agbaji O, Agwu KK. Sonographic characterization of renal pathologies in HIV/AIDS in Plateau State, Nigeria. Niger J Med. 2012; 21:160-164.
86. Raimann JG, Kirisits W, Gebetsroither E, et al. Saliva urea dipstick test: application in chronic kidney disease. Clin Nephrol. 2011;76:23-28.
87. Banks CE, Randviir EP. Detection of creatinine: technologies for point-of-care determination of glomerular filtration. Bioanalysis. 2014; 6:109-111.
88. Gous N, Scott L, Potgieter J, et al. Feasibility of performing multiple point of care testing for HIV anti-retroviral treatment initiation and monitoring from multiple or single fingersticks. PLoS One. 2013;8: e85265.
89. Paragas N, Nickolas TL, Wyatt C, et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol. 2009;20: 1687-1692.
90. Sola-Del Valle DA, Mohan S, Cheng JT, et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011;26:2387-2390.
91. Peralta C, Scherzer R, Grunfeld C, et al. Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women's Inter-agency HIV Study (WIHS). HIV Med. 2014;15:291-300.
92. Jablonowska E, Wojcik K, Piekarska A. Urine Liver-Type Fatty Acid-Binding protein and kidney injury Molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir. AIDS Res Hum Retroviruses. 2014;30:363-369.
93. Clerico A, Galli C, Fortunato A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med. 2012;50:1505-1517.
94. van de Vijver S, Oti S, Addo J, et al. Review of community-based interventions for prevention of cardiovascular diseases in low-and middle-income countries. Ethn Health. 2012;17:651-676.
95. Emdin CA, Chong NJ, Millson PE. Non-physician clinician provided HIV treatment results in equivalent outcomes as physician-provided care: a meta-analysis. J Int AIDS Soc. 2013;16:18445.
96. Taler SJ, Agarwal R, Bakris GL, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201-213.
97. Abu-Aisha H, Elamin S. Peritoneal dialysis in Africa. Perit Dial Int. 2010;30:23-28.
98. Kalyesubula R, Odiit A, Wekeesa C, et al. A time to improve kidney care and awareness in Uganda. Dial Times. 2012;03:1-4. Available at: http://www.renalresearch.com/idc/idcplg?IdcService=GET-FILE& Rendition=Web&RevisionSelectionMethod=Latest&dDocName=PDF- 300046050. Accessed July 20, 2013.
99. Luyckx VA, Naicker S, McKee M. Equity and economics of kidney disease in sub-Saharan Africa. Lancet. 2013;382:103-104.
100. Moosa MR, Kidd M. The dangers of rationing dialysis treatment: the dilemma facing a developing country. Kidney Int. 2006;70:1107-1114.
101. Carter M, Callegari J. Proposed treatment program for acute renal failure (ARF) in the United Republic of Tanzania as a model for sub-Saharan Africa. J Hosp Mark Public Relations. 2007;18:81-88.
102. Mcligeyo SO. Initial experience with CAPD in patients with HIV infection in a developing country. Perit Dial Int. 1992;12:267-268.
103. Callegari JG, Kilonzo KG, Yeates KE, et al. Peritoneal dialysis for acute kidney injury in sub-Saharan Africa: challenges faced and lessons learned at Kilimanjaro Christian Medical Centre. Kidney Int. 2012;81:331-333.
104. Carter M, Kilonzo K, Odiit A, et al. Acute peritoneal dialysis treatment programs for countries of the East African community. Blood Purif. 2012;33:149-152.
105. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004-2014.
106. Muller E, Barday Z, Mendelson M, et al. Renal transplantation between HIV-positive donors and recipients justified. S Afr Med J. 2012;102: 497-498.
107. Katz IJ, Gerntholtz TE, van Deventer M, et al. Is there a need for early detection programs for chronic kidney disease? Clin Nephrol. 2010;74 (suppl 1):S113-S118.
108. Bonita R, Magnusson R, Bovet P, et al. Country actions to meet UN commitments on non-communicable diseases: a stepwise approach. Lancet. 2013;381:575-584.
109. Heyns CF, Fisher M. The urological management of the patient with acquired immunodeficiency syndrome. BJU Int. 2005;95:709-716.
110. Labib MA, Silumbe M, Bowa K. The Short-term outcome of urethral stricture disease management in HIV and non-HIV infected patients: a comparative study. UTJ. 2013;6:18-22.
111. Bowa K, Kachimba J, Labib M, et al. The changing pattern of Urolog-ical Cancers in Zambia. Medicial J Zambia. 2009;35:157-159.
112. Downs JA, Mguta C, Kaatano GM, et al. Urogenital schistosomiasis in women of reproductive age in Tanzania's Lake Victoria region. Am J Trop Med Hyg. 2011;84:364-369.
113. Emmanoulides C, Miles SA, Mitsuyasu RT. Pathogenesis of AIDS-related Kaposi's sarcoma. Oncology (Williston Park). 1996;10:335-341; discussion: 342-350.
114. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839.
115. Lekoubou A, Awah P, Fezeu L, et al. Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa. Int J Environ Res Public Health. 2010;7:353-363.
116. Naicker S, Eastwood JB, Plange-Rhule J, et al. Shortage of healthcare workers in sub-Saharan Africa: a nephrological perspective. Clin Neph-rol. 2010;74(suppl 1):S129-S133.
117. WHO. The World Health Report 2006-working together for health. 2006. Available at: http://www.who.int/whr/2006/en/. Accessed July 20, 2013.
118. Kengne AP, Ntyintyane LM, Mayosi BM. A systematic overview of prospective cohort studies of cardiovascular disease in sub-Saharan Africa. Cardiovasc J Afr. 2012;23:103-112.
119. Yahaya I, Uthman OA, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev. 2013;1:CD007183.
120. Teo YY, Small KS, Kwiatkowski DP. Methodological challenges of genome-wide association analysis in Africa. Nat Rev Genet. 2010;11:149-160.
121. Bowa K, Labib M, Munalula BK, et al. HIV and male infertility at the University Teaching Hospital Lusaka. East Central Africa J Surg. 2008; 13:65-68.
122. Gilks CF, Walker AS, Dunn DT, et al. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17:1363-1373.
123. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012;205:1739-1744.
124. Harris DCH, Dupuis S, Couser WG. Training nephrologists from developing countries: does it have a positive impact? Kidney Int Suppl. 2012; (suppl 2):275-278.
125. Dalal S, Beunza JJ, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol. 2011;40:885-901.
126. Paulus JK, Santoyo-Vistrain R, Havelick D, et al. Global teaching and training initiatives for emerging cohort studies. J Epidemiol Glob Health. 2012;2:125-133.
127. Dalal S, Holmes MD, Ramesar RS. Advancing public health genomics in Africa through prospective cohort studies. J Epidemiol Community Health. 2010;64:585-586.
128. Asiki G, Murphy G, Nakiyingi-Miiro J, et al. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol. 2013;42:129-141.
129. Cornell M, Technau K, Fairall L, et al. Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:653-660.